



**HAL**  
open science

## **DHA-derived oxylipins, neuroprostanes and protectins, differentially and dose-dependently modulate the inflammatory response in human macrophages: putative mechanisms through PPAR activation**

Rémy Bosviel, Laurie Joumard-Cubizolles, Giulia Chinetti-Gbaguidi, Dominique Bayle, Corinne Copin, Nathalie Hennuyer, Isabelle Duplan, Bart Staels, Giuseppe Zanoni, Alessio Porta, et al.

### ► **To cite this version:**

Rémy Bosviel, Laurie Joumard-Cubizolles, Giulia Chinetti-Gbaguidi, Dominique Bayle, Corinne Copin, et al.. DHA-derived oxylipins, neuroprostanes and protectins, differentially and dose-dependently modulate the inflammatory response in human macrophages: putative mechanisms through PPAR activation. *Free Radical Biology and Medicine*, 2017, 103, pp.146-154. 10.1016/j.freeradbiomed.2016.12.018 . hal-01595235

**HAL Id: hal-01595235**

**<https://hal.science/hal-01595235v1>**

Submitted on 3 Jun 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# DHA-derived oxylipins, neuroprostanes and protectins, differentially and dose-dependently modulate the inflammatory response in human macrophages: Putative mechanisms through PPAR activation

Rémy Bosviel<sup>a,b</sup>, Laurie Joumard-Cubizolles<sup>a,b</sup>, Giulia Chinetti-Gbaguidi<sup>c,d</sup>, Dominique Bayle<sup>a,b</sup>, Corinne Copin<sup>c</sup>, Nathalie Hennuyer<sup>c</sup>, Isabelle Duplan<sup>c</sup>, Bart Staels<sup>c</sup>, Giuseppe Zanoni<sup>e</sup>, Alessio Porta<sup>e</sup>, Laurence Balas<sup>f</sup>, Jean-Marie Galano<sup>f</sup>, Camille Oger<sup>f</sup>, Andrzej Mazur<sup>a,b</sup>, Thierry Durand<sup>f</sup>, Cécile Gladine<sup>a,b,\*</sup>

<sup>a</sup> INRA, UMR 1019, UNH, CRNH Auvergne, F-63000 Clermont-Ferrand, France

<sup>b</sup> Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, BP 10448, F-63000 Clermont-Ferrand, France

<sup>c</sup> Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, F-59000 Lille, France

<sup>d</sup> University of Côte d'Azur, CHU, Inserm, CNRS, IRCAN, France

<sup>e</sup> University of Pavia, Pavia, Italy

<sup>f</sup> IBMM, UMR 5247 CNRS/UM/ENSCM, Montpellier, France

## ARTICLE INFO

### Keywords:

Omega 3 PUFAs  
DHA  
Oxylipins  
Lipid mediators  
Free-radical mediated oxygenation  
Neuroprostanes  
Protectins  
Inflammation  
PPARs

## ABSTRACT

Whereas the anti-inflammatory properties and mechanisms of action of long chain  $\omega$ 3 PUFAs have been abundantly investigated, research gaps remain regarding the respective contribution and mechanisms of action of their oxygenated metabolites collectively known as oxylipins. We conducted a dose-dependent and comparative study in human primary macrophages aiming to compare the anti-inflammatory activity of two types of DHA-derived oxylipins including the well-described protectins (NPD1 and PDX), formed through lipoxygenase pathway and the neuroprostanes (14-A<sub>4t</sub>- and 4-F<sub>4t</sub>-NeuroP) formed through free-radical mediated oxygenation and expected to be new anti-inflammatory mediators. Considering the potential ability of these DHA-derived oxylipins to bind PPARs and knowing the central role of these transcription factors in the regulation of macrophage inflammatory response, we performed transactivation assays to compare the ability of protectins and neuroprostanes to activate PPARs. All molecules significantly reduced mRNA levels of cytokines such as IL-6 and TNF- $\alpha$ , however not at the same doses. NPD1 showed the most effect at 0.1  $\mu$ M (-14.9%,  $p < 0.05$  for IL-6 and -26.7%,  $p < 0.05$  for TNF- $\alpha$ ) while the three other molecules had greater effects at 10  $\mu$ M, with the strongest result due to the cyclopentenone neuroprostanone, 14-A<sub>4t</sub>-NeuroP (-49.8%,  $p < 0.001$  and -40.8%,  $p < 0.001$ , respectively). Part of the anti-inflammatory properties of the DHA-derived oxylipins investigated could be linked to their activation of PPARs. Indeed, all tested oxylipins significantly activated PPAR $\gamma$ , with 14-A<sub>4t</sub>-NeuroP leading to the strongest activation, and NPD1 and PDX also activated PPAR $\alpha$ . In conclusion, our results show that neuroprostanes and more especially cyclopentenone neuroprostanes have potent anti-inflammatory activities similar or even more pronounced than protectins supporting that neuroprostanes should be considered as important contributors to the anti-inflammatory effects of DHA.

**Abbreviations:** AP-1, activator protein 1; B94, TNFAIP2, TNF alpha induced protein 2; C/EBP, CCAAT-enhancer-binding protein; CCL, chemokine ligand; CEX-1, chemokine exodus protein 1; COX, cyclooxygenase; CXCL, chemokine (C-X-C motif) ligand; CYP, cytochrome P450 monooxygenase; DHA, docosahexaenoic acid; ELISA, enzyme linked immunosorbent assay; EPA, eicosapentaenoic acid; FA, fatty acid; FCS, fetal calf serum; IFN $\gamma$ , interferon gamma; IKK, I $\kappa$ B kinase; IL, interleukin; iNOS, inducible nitric oxide synthase; I $\kappa$ B $\alpha$ , inhibitor of kappa B alpha; LC- $\omega$ 3 PUFAs, long chain omega-3 polyunsaturated fatty acids; LOX, lipoxygenase; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein 1; NeuroP, neuroprostanone; NF $\kappa$ B, nuclear factor kappa B; NPD1, neuroprotectin D1; PBMC, peripheral blood mononuclear cells; PDX, protectin DX; PPAR, Peroxisome Proliferator-Activated Receptor; PPRE, PPAR response element; sEH, soluble epoxyde hydrolase; STAT, signal transducer and activator of transcription; TNF- $\alpha$ , tumor necrosis factor alpha

\* Correspondence to: INRA, Centre INRA Auvergne Rhône Alpes, Site de Theix, UMR 1019, Unité de Nutrition Humaine, 63 122 Saint Genès Champanelle, France.

**E-mail addresses:** [remy.bosviel@gmail.com](mailto:remy.bosviel@gmail.com) (R. Bosviel), [laurie.cubizolles@udamail.fr](mailto:laurie.cubizolles@udamail.fr) (L. Joumard-Cubizolles), [giulia.chinetti@unice.fr](mailto:giulia.chinetti@unice.fr) (G. Chinetti-Gbaguidi), [dominique.bayle@inra.fr](mailto:dominique.bayle@inra.fr) (D. Bayle), [corinne.copin@pasteur-lille.fr](mailto:corinne.copin@pasteur-lille.fr) (C. Copin), [nathalie.hennuyer@pasteur-lille.fr](mailto:nathalie.hennuyer@pasteur-lille.fr) (N. Hennuyer), [isabelle.duplan@pasteur-lille.fr](mailto:isabelle.duplan@pasteur-lille.fr) (I. Duplan), [bart.staels@pasteur-lille.fr](mailto:bart.staels@pasteur-lille.fr) (B. Staels), [gzanoni@unipv.it](mailto:gzanoni@unipv.it) (G. Zanoni), [a.porta@unipv.it](mailto:a.porta@unipv.it) (A. Porta), [balas@univ-montp1.fr](mailto:balas@univ-montp1.fr) (L. Balas), [jean-marie.galano@univ-montp1.fr](mailto:jean-marie.galano@univ-montp1.fr) (J.-M. Galano), [camille.oger@univ-montp1.fr](mailto:camille.oger@univ-montp1.fr) (C. Oger), [andre.mazur@inra.fr](mailto:andre.mazur@inra.fr) (A. Mazur), [thierry.durand@umontpellier.fr](mailto:thierry.durand@umontpellier.fr) (T. Durand), [cecile.gladine@inra.fr](mailto:cecile.gladine@inra.fr) (C. Gladine).

## 1. Introduction

Evidences suggest that increased consumption of LC- $\omega$ 3 PUFAs, notably DHA [1], reduces chronic inflammation and the incidence of inflammation-linked disorders such as atherosclerosis or metabolic syndrome [1,2]. The anti-inflammatory effects of LC- $\omega$ 3 PUFAs include the decrease of immune cell chemotaxis, the inhibition of leukocytes/endothelium adhesive interactions and the moderation of macrophage pro-inflammatory activity. For instance, several *in vitro* experiments with PBMC, neutrophils or monocytes isolated from the blood of healthy subjects consuming daily supplements of EPA and DHA showed significant reduction (up to 75%) of leukotriene B<sub>4</sub> chemoattractant production [3,4]. *Ex-vivo* treatment with LC- $\omega$ 3 PUFAs has also been associated with reduced levels of several pro-inflammatory cytokines and chemokines including TNF- $\alpha$ , IL-1 $\beta$ , IL-6 or MCP-1 by approximately 40 to 80% in PBMC or mononuclear cells from healthy men or women supplemented with EPA and DHA daily for 4 weeks to up to 3 months [5–7]. The mechanisms of action underlying the anti-inflammatory properties of LC- $\omega$ 3 PUFAs have been mostly linked to the altered activation of NF $\kappa$ B [2], one of the main transcription factors regulating the expression of pro-inflammatory mediators [8]. This is notably mediated by the activation of PPAR $\alpha$  and PPAR $\gamma$  which physically interact with NF $\kappa$ B preventing its nuclear translocation [2]. Independently to NF $\kappa$ B, PPARs also directly modulate immune and inflammatory response in macrophages *via* protein/protein interactions with transcription factors controlling pro-inflammatory genes such as AP-1, C/EBP and STAT, a phenomenon called *trans*-repression. PPARs can also regulate transcription *via trans*-activation by binding, in a ligand-dependent manner, to DNA response elements (PPRE) in the promoter or enhancer regions of target genes [9,10].

Whereas the biological properties and putative mechanisms of action of LC- $\omega$ 3 PUFAs have been abundantly investigated, research gaps remain especially regarding the roles and mechanisms of action of their oxygenated metabolites collectively known as oxylipins. Oxylipins refer to a superclass of lipid mediators (hundreds of metabolites) produced from oxygenation of PUFAs. They include the prostanoids and thromboids produced by COXs, leukotrienes, resolvins, hepoxilins and mid-chain hydroxy-FA generated by LOXs, epoxy-FA and omega-terminal hydroxy-FA produced by several CYPs as well as iso/neuroprostanes resulting from the free-radical-mediated oxidation of PUFAs [11,12]. DHA in particular is not a good COX substrate but it is readily oxygenated by LOX, CYPs as well as free-radical mediated pathways giving rise to an array of oxylipins. From the LOX pathway, DHA gives rise to D serie resolvins, maresins and protectins *via* further LOX and epoxygenation steps. Protectin D1 is produced *via* LOX, epoxide formation from the hydroperoxide product and epoxide hydrolase activity while protectin DX is formed *via* double LOX activity [13]. DHA is also readily oxygenated *via* CYP epoxygenase activity, yielding epoxy FAs which can be converted to dihydroxy FAs *via* sEH. CYP v-hydroxylase activity produces hydroxy-docosahexaenoic acid with hydroxyl groups near the methyl end of DHA [14]. Finally, because of its high number of double bonds, DHA is very prone to peroxidation yielding neuroprostanes which include a total of 128 theoretical compounds categorized into 8 regioisomers series (4, 7, 10, 11, 13, 14, 17 or 20) among which levels of 4- and 20-series are predominant *in vivo* [15]. A large body of evidence suggests that oxylipins might be the effective mediators of the anti-inflammatory properties of EPA and DHA. The group of Sethi et al. was the first to demonstrate that the autooxidation of EPA and DHA (induced by *ex-vivo* oxidation of the native FAs with CuSO<sub>4</sub> and ascorbic acid) was a mandatory prerequisite to induce a reduction of the adhesion of U937 monocytes to endothelial cells *via* a decreased expression of adhesion molecules [16]. More recently, enzymatic oxylipins derived from EPA and DHA (resolvins, protectins and maresins), have been examined extensively in cell culture and animal models of inflammation and have been identified as potent anti-inflammatory and inflammation resolving lipid mediators

[17]. Interestingly, several studies showed that LC- $\omega$ 3 PUFA-derived oxylipins might act, at least in part, through PPAR dependent mechanisms [18–22] which is consistent with reporter assay and *in silico* studies showing that oxidized metabolites of PUFAs are good PPAR ligands [23,24]. Direct evidence regarding the biological activity and mechanisms of action of non-enzymatic oxylipins are much scarcer but a study performed by the group of Morrow as well as our previous results on atherosclerotic mice [25] also support the fact that the specific DHA-derived oxylipins called neuroprostanes might also have anti-inflammatory activities through a mechanism involving NF $\kappa$ B [26] and PPARs [27].

In the present study, we focused our attention on oxylipins derived from DHA rather than EPA because of its more potent anti-inflammatory activity [1] and its higher susceptibility to produce the non-enzymatic oxylipin neuroprostanes [28] expected to be new anti-inflammatory mediators of interest [17]. The main objectives of our study were (1) to compare, in human primary macrophages, the anti-inflammatory properties of neuroprostanes to the well-described protectins and (2) to investigate the dose-response relationship. Moreover, since PPARs might be one of the multiple targets of oxylipins, we assessed the ability of the DHA-derived oxylipins to bind and activate PPARs using docking *in silico* tests and transient transfection assays.

## 2. Materials and methods

### 2.1. Synthesis of DHA-derived oxylipins

14-A<sub>4t</sub>-NeuroP, was synthesized by Dr. G. Zanoni's laboratory as previously described [29], 4-F<sub>4t</sub>-NeuroP and NPD1 were synthesized by Dr. T. Durand's laboratory as previously described [30,31] while PDX was purchased from Cayman Chemical (via Bertin Pharma, Montigny le Bretonneux, France). Stock solutions (20 mM) were prepared in ethanol and stored at –80 °C.

### 2.2. Cell culture

#### 2.2.1. Human primary monocyte-derived macrophages

Mononuclear cells were isolated from buffy coats from healthy donors (French Blood Service, Saint-Etienne, France) [32]. After Ficoll (GE Healthcare, ref: 17144002, Fisher Scientific, Illkirch-Graffenstaden, France) gradient centrifugation, the monocytes were suspended in RPMI 1640 medium containing gentamycin (0.1 mg/mL, Gibco, ref: 15710049, Fisher Scientific), glutamine (2 mM, Gibco, ref: 11500-626, Fisher Scientific) and 10% decomplexed pooled human serum (ref: S4190-100, Dominique Dutscher, Brumath, France). Cells were cultured at a density of  $3 \times 10^6$  cells/well in Corning® Primaria™ 6-well plastic culture dishes (BD Falcon™, ref: 353846, Dominique Dutscher). Differentiation of monocytes into macrophages occurred spontaneously by adhesion of cells to the culture dish. Mature monocyte-derived macrophages were used for experiments after 7 days of culture. For treatment with the different DHA-derived oxylipins, medium was changed to RPMI 1640 medium containing gentamycin (0.1 mg/mL) and glutamine (2 mM) (Gibco, Fisher Scientific) and different concentrations of oxylipins (i.e. 0.1, 1 or 10  $\mu$ M) were added. According to the literature reporting short half-lives of oxylipins (in the range of seconds) and their relative instability in cell culture medium [26] and based on our preliminary results (data not shown), the DHA-derived oxylipins were added to the macrophages 30 min before the induction of inflammatory response with LPS (100 ng/mL, 6 h, ref: L2654, Sigma-Aldrich, Saint Quentin Fallavier, France). As eicosanoids may rapidly react with albumin [33], serum-free medium was used in these steps. At the end of the treatments, supernatants were harvested for ELISA and cells were processed for RNA extraction.

#### 2.2.2. Cos-7 cells

To demonstrate the ability of the DHA-derived oxylipins to activate

PPARs, COS-7 cells, a cell model that can be easily and reproducibly transfected and that is more robust than primary macrophages, has been used. Cos-7 cells, obtained from ATCC (CRL-1651, LGC Standards, Molshheim, France) were seeded in 60 mm dishes at a density of  $5.5 \times 10^5$  cells/dish in DMEM medium (ref: 41965, Gibco, Fisher Scientific) supplemented with 10% fetal calf serum (FCS, ref: SV30160.03, Hyclone, GE Healthcare Life Sciences, Fisher Scientific) and incubated at 37 °C, 5% CO<sub>2</sub> for 16 h prior to transfection. Cells were transfected in DMEM medium, using jetPEI transfection reagent (ref: 101-10, Polyplus, Ozyme, Saint Quentin Yvelines, France), with reporter (pG5-TK-pGL3) and pGal4-hPPAR $\alpha$ , pGal4-hPPAR $\gamma$  or pGal4-hPPAR $\delta$  expression plasmids constructed as previously described [34]. Briefly, hPPAR domains were subcloned in the plasmid pBD-Gal4 and the obtained chimera was subcloned in the pCDNA vector. The pCMV- $\beta$ -galactosidase expression plasmid (ref: 631719, Clontech, Ozyme) was co-transfected as a control for transfection efficiency. After 16 h, transfection was stopped by addition of DMEM medium supplemented with 10% FCS and cells were then trypsinized, seeded in 96 wells plates and then incubated overnight in DMEM medium without FCS containing increasing concentrations (0.1–20  $\mu$ M) of 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP, NPD1, PDX or vehicle (DMSO). WY 14.643 (10  $\mu$ M, Chemsyn Science Laboratories, Lenexa, KS, USA), Rosiglitazone (1  $\mu$ M, Sigma-Aldrich) and GW 501516 (1  $\mu$ M, Calbiochem, Merck, Fontenay sous Bois, France) were used as positive control of PPAR $\alpha$ , PPAR $\gamma$  and PPAR $\delta$  activation [35–37].

respectively. At the end of the experiment, cells were washed once with ice-cold PBS, lysed and luciferase and  $\beta$ -galactosidase assays were performed as previously described [38].

### 2.3. RNA extraction and analysis

Total cellular RNA was extracted from macrophages using Trizol reagent (ref: 12044977, Fisher Scientific) following the instructions of the manufacturer. For qRT-PCR analysis of TNF- $\alpha$ , IL-6, COX-2, MCP-1 and CCL-3 expression, total RNAs were submitted to DNase treatment using the Thermo Scientific RNase free DNase I kit (ref: 10649890, Fisher Scientific), according to manufacturer's instructions, reverse transcribed (RT) using Applied Biosystems™ High-Capacity cDNA Reverse Transcription Kit (ref: 10400745, Fisher Scientific) and subsequently amplified by real-time quantitative polymerase chain reaction (qPCR) on an AB 7900 apparatus (Applied Biosystems) using specific primers (Table 1) and Agilent Technologies Brilliant III ultra FAST kit (ref: 600882, Agilent Technologies, Les Ulis, France) with a 60 °C elongation temperature. The relative expression of each gene was normalized to the expression level of cyclophilin and calculated by the  $\Delta C_t$  method. The  $\Delta C_t$  is expressed as the difference between the  $C_t$  (threshold cycle) of the indicated target gene and the  $C_t$  of cyclophilin. The amount of target gene relative to the cyclophilin was expressed as  $2^{-(\Delta\Delta C_t)}$ .

### 2.4. ELISA test

MCP-1 and TNF- $\alpha$  secreted in cell culture supernatants were quantified using enzyme linked immunosorbent assays (ELISA) purchased from R & D Systems (DY279 and DY210, respectively, Abingdon,

UK) according to the instructions of the manufacturer.

### 2.5. Statistical analysis

Data are presented as mean  $\pm$  standard deviation (SD). Comparisons between groups were analyzed using Student's *t*-test and statistical significance was established at  $p < 0.05$ . For gene expression and ELISA assays, all conditions were compared to vehicle 30 min, LPS 6 h experimental condition. For PPAR transfection assays, all conditions were compared to vehicle treated cells.

## 3. Results

The anti-inflammatory effects of the four DHA-derived oxylipins (i.e. the non-enzymatic 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP and the enzymatic PDX and NPD1), were evaluated by analyzing the expression and secretion of selected pro-inflammatory markers in primary human monocyte-derived macrophages after a 6 h treatment with LPS (100 ng/mL). As expected, LPS induced drastic increases (compared to control vehicle treated cells) of all markers, at the mRNA (TNF- $\alpha$ :  $\times 92$ ,  $p < 0.001$ ; IL-6:  $\times 819$ ,  $p < 0.001$ ; MCP-1:  $\times 9$ ,  $p < 0.001$ ; COX-2:  $\times 182$ ,  $p < 0.001$ ; CCL-3:  $\times 47$ ,  $p < 0.001$ ) and protein (TNF- $\alpha$ :  $\times 70.0$ ,  $p < 0.001$  and MCP-1:  $\times 3.7$ ,  $p < 0.01$ ) levels.

### 3.1. Dose-dependent effects of DHA-derived oxylipins on mRNA levels of pro-inflammatory markers


In order to investigate the ability of DHA-derived oxylipins to modulate the inflammatory response induced by LPS, monocyte-derived macrophages were pre-incubated with the DHA-derived oxylipins (30 min) before LPS-induced inflammation.

Results of gene expression obtained with the highest dose of DHA-derived oxylipins (i.e. 10  $\mu$ M) are showed in Fig. 1. Interestingly, the strongest effects were obtained with the cyclopentenone neuroprostane, 14-A<sub>4t</sub>-NeuroP, which caused substantial decreases of IL-6 ( $-49.8\%$ ,  $p < 0.001$ ), TNF- $\alpha$  ( $-40.8\%$ ,  $p < 0.001$ ), MCP-1 ( $-58.8\%$ ,  $p < 0.001$ ), CCL-3 ( $-21.7\%$ ,  $p < 0.01$ ) and COX-2 ( $-26.7\%$ ,  $p < 0.01$ ) mRNA. The other neuroprostane, 4-F<sub>4t</sub>-NeuroP, also reduced mRNA levels of IL-6 ( $-30.6\%$ ,  $p < 0.01$ ), TNF- $\alpha$  ( $-18.9\%$ ,  $p < 0.05$ ) and MCP-1 ( $-34.2\%$ ,  $p < 0.01$ ). Concerning the enzymatic oxylipins, pre-incubation with PDX significantly decreased IL-6 ( $-42.9\%$ ,  $p < 0.05$ ), TNF- $\alpha$  ( $-52.3\%$ ,  $p < 0.05$ ) and MCP-1 ( $-54.2\%$ ,  $p < 0.05$ ) whereas NPD1 had no significant effect on the mRNA levels of all tested pro-inflammatory markers.

At lower doses (i.e. 0.1 and 1  $\mu$ M), the DHA-derived oxylipins had less pronounced effects on mRNA expression except for NPD1 (Table 2). More precisely, at 1  $\mu$ M concentration, 4-F<sub>4t</sub>-NeuroP reduced IL-6 ( $-24.5\%$ ,  $p < 0.05$ ) while NPD1 and PDX reduced CCL3 ( $-30.4\%$  and  $-25.6\%$ ,  $p < 0.05$ , respectively). With 0.1  $\mu$ M doses, 14-A<sub>4t</sub>-NeuroP reduced MCP-1 mRNA ( $-23.8\%$ ,  $p < 0.001$ ) and NPD1, that was inactive at 10  $\mu$ M, showed important effects with reduced IL-6 ( $-14.9\%$ ,  $p < 0.05$ ), TNF- $\alpha$  ( $-26.7\%$ ,  $p < 0.05$ ) and COX-2 ( $-38.7\%$ ,  $p < 0.05$ ) mRNA.

**Table 1**  
List of primers used for mRNA analysis.

Target mRNA	Primer forward (5' to 3')	Primer reverse (5' to 3')
Cyclophilin	GCATACGGGTCTGGCATCTTGTC	ATGGTGATCTTCTGCTGGTCTTGC
IL-6	AAGTCCTGATCCAGTTCCTG	GATGAGTTGTCATGTCCTGC
TNF- $\alpha$	CAGAGGGCCGTACCTCATC	GGAAGACCCCTCCAGATAG
MCP-1	TCATAGCAGCCACCTTCATTCC	GGACACTGCTGCTGGTGATTCC
COX-2	TGAGCATCTACGGTTTGCTG	TGCTTGCTGGAAACAACCTGC
CCL-3	TGCAACCAGTTCCTGCATC	TTTCTGGACCACTCCTCAC




**Fig. 1.** Percentage of IL-6, TNF- $\alpha$ , MCP-1, CCL-3 and COX-2 mRNA levels in human monocyte-derived macrophages pre-exposed for 30 min with 10  $\mu$ M of 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP, NPD1 or PDX before the induction of inflammatory response with LPS (100 ng/mL, 6 h), in comparison with macrophages pre-exposed to vehicle alone. Results are means of at least 5 independent experiments using cells from different donors. Student's *t*-test (comparison to vehicle 30 min, LPS 6 h condition). \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

**Table 2**  
Percentage of IL-6, TNF- $\alpha$ , MCP-1, CCL-3 and COX-2 mRNA levels in human monocyte-derived macrophages pre-exposed for 30 min with 0.1 or 1  $\mu$ M of 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP, NPD1 or PDX before the induction of inflammatory response with LPS (100 ng/mL, 6 h), in comparison with macrophages pre-exposed to vehicle alone. Results are means of at least 5 independent experiments using cells from different donors.

	14-A <sub>4t</sub> -NeuroP				4-F <sub>4t</sub> -NeuroP				NPD1				PDX								
	0.1		1		0.1		1		0.1		1		0.1		1						
	RE (%)	SD (%)	<i>p</i>	RE (%)	SD (%)	<i>p</i>	RE (%)	SD (%)	<i>p</i>	RE (%)	SD (%)	<i>p</i>	RE (%)	SD (%)	<i>p</i>						
IL-6	95.4	35.6	0.789	102.0	29.4	0.887	99.6	16.4	0.960	75.5	12.0	0.017	80.5	35.4	0.235	97.1	52.1	0.907	72.3	28.7	0.097
TNF- $\alpha$	104.7	34.6	0.752	85.9	26.5	0.251	102.5	28.8	0.841	86.0	19.6	0.011	116.4	106.4	0.697	82.3	25.5	0.195	72.0	43.0	0.284
MCP-1	76.2	7.7	0.001	83.4	22.2	0.126	80.7	20.0	0.097	100.4	55.2	0.473	92.6	54.6	0.732	109.3	59.3	0.716	88.6	69.7	0.706
CCL3	88.7	25.4	0.379	98.7	34.0	0.937	92.6	26.1	0.562	78.0	33.0	0.229	69.6	28.0	0.045	106.4	33.1	0.686	74.2	20.0	0.044
COX-2	102.3	62.7	0.932	97.0	41.0	0.865	101.9	41.5	0.916	111.9	26.8	0.017	73.6	51.9	0.268	108.5	35.1	0.617	64.5	33.8	0.126

RE: relative expression.



**Fig. 2.** Percentage of TNF- $\alpha$  and MCP-1 secreted protein levels by human monocyte-derived macrophages pre-exposed for 30 min with 10  $\mu$ M of 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP, NPD1 or PDX before the induction of inflammatory response with LPS (100 ng/mL, 6 h), in comparison with macrophages pre-exposed to vehicle alone. Results are means of at least 5 independent experiments using cells from different donors. Student's *t*-test (comparison to vehicle 30 min, LPS 6 h condition). \* *p* < 0.05; \*\* *p* < 0.01; \*\*\* *p* < 0.001.

### 3.2. Dose-dependent effects of DHA-derived oxylipins on the secretion of TNF- $\alpha$ and MCP-1

ELISA assays were used to investigate the effects of the four DHA-derived oxylipins on LPS-induced secretion of two main pro-inflammatory cytokines and chemokines, i.e. TNF- $\alpha$  and MCP-1. Overall, it should be noted that the effects at the protein level (Fig. 2) for TNF- $\alpha$  were less pronounced than the effects described above at the mRNA level. However, consistently with the previous results, both 14-A<sub>4t</sub>-NeuroP and 4-F<sub>4t</sub>-NeuroP at 10  $\mu$ M reduced TNF- $\alpha$  secretion (−12.4%, *p* < 0.05; −13.9%, *p* < 0.01). Surprisingly, NPD1 also induced a significant decrease of TNF- $\alpha$  secretion (−23.9%, *p* < 0.05) and PDX had no effect. At lower concentration, none of the DHA-derived oxylipins induced significant decrease of TNF- $\alpha$  secretion (Table 3).

Effects of the four DHA-derived oxylipins on MCP-1 protein levels matched those on mRNA level for the 10  $\mu$ M dose: 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP and PDX reduced MCP-1 secretion (−36.1%, *p* < 0.01; −28.5%, *p* < 0.01 and −55%, *p* < 0.001 respectively).

At lower concentrations however, only PDX induced significant decreases of MCP-1 secretion, with a −39.5% (*p* < 0.05) reduction at 1  $\mu$ M and a −56% (*p* < 0.01) reduction at 0.1  $\mu$ M (Table 3).

### 3.3. Ability of DHA-derived oxylipins to bind to and activate PPARs


Activation of the PPARs is one of the three mechanisms through which LC- $\omega$ 3 PUFAs potentially exert their anti-inflammatory properties [2] and several studies suggest that LC- $\omega$ 3 PUFA-derived oxylipins might activate PPARs [18–22].

To assess whether 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP, NPD1 and PDX are effective PPAR ligands, transient transfections of a luciferase reporter vector with hPPAR $\alpha$ , hPPAR $\gamma$  or hPPAR $\delta$  expression vectors were performed in Cos-7 cells. In all experiments, the agonists of the tested receptor, i.e. respectively WY 14.643 (10  $\mu$ M), rosiglitazone (1  $\mu$ M) and GW501516 (1  $\mu$ M), drastically induced the transcriptional activity of luciferase reporter vector in Cos-7 cells ( $\times 1.4 \times 10^{18}$ , *p* < 0.001;

**Table 3** Percentage of TNF- $\alpha$  and MCP-1 protein levels secreted by human monocyte-derived macrophages pre-exposed for 30 min with 0.1 or 1  $\mu$ M of 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP, NPD1 or PDX before the induction of inflammatory response with LPS (100 ng/mL, 6 h), in comparison with macrophages pre-exposed to vehicle alone. Results are means of at least 5 independent experiments using cells from different donors.

	14-A <sub>4t</sub> -NeuroP			4-F <sub>4t</sub> -NeuroP			NPD1			PDX											
	0.1	1	1	0.1	1	1	0.1	1	0.1	1	1										
	RS (%)	SD (%)	<i>P</i>	RS (%)	SD (%)	<i>P</i>	RS (%)	SD (%)	<i>P</i>	RS (%)	SD (%)	<i>P</i>									
TNF- $\alpha$	110.8	13.8	0.113	103.5	14.9	0.594	96.3	11.6	0.513	96.0	19.9	0.641	101.7	11.9	0.795	91.3	12.3	0.146	77.9	29.4	0.167
MCP-1	84.0	40.7	0.380	100.3	54.1	0.990	89.4	31.9	0.453	100.4	47.4	0.986	89.4	84.2	0.848	44.0	34.3	0.010	60.5	26.9	0.030

RS: relative secretion.



**Fig. 3.** Induction of luciferase activity by pGal4/hPPAR $\alpha$ , pGal4/hPPAR $\gamma$  or pGal4/hPPAR $\delta$  constructs in Cos-7 cells (reported as a percentage of the induction found with WY14.643  $10^{-5}$  M, rosiglitazone  $10^{-6}$  M or GW501516  $10^{-6}$  M, respectively) exposed to varying concentrations of 14-A $_4$ t-NeuroP, 4-F $_4$ t-NeuroP, NPD1 and PDX. Experiments were performed in triplicates. Student's *t*-test (compared to vehicle condition). \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

$\times 2.2 \times 10^{17}$ ,  $p < 0.001$  and  $\times 6.4 \times 10^{17}$ ,  $p < 0.001$ , respectively).

All assayed oxylipins led to the induction of the transcriptional activity of luciferase reporter vector in Cos-7 cells transfected with the hPPAR $\gamma$  expression vector (Fig. 3). 14-A $_4$ t-NeuroP showed again the

most effect with significant induction at 1, 5 and 10  $\mu$ M, attaining a maximum, equivalent to 23.3% of the induction obtained with 1  $\mu$ M rosiglitazone. Lower inductions were obtained when Cos-7 cells were treated with 4-F $_4$ t-NeuroP, NPD1 and PDX (with maximal induction representing 7.2%, 5.5% and 13.3% of 1  $\mu$ M rosiglitazone activation, respectively) and were significant only at 5 and 10  $\mu$ M.

In experiments using the hPPAR $\alpha$  expression vector, 14-A $_4$ t-NeuroP only induced slightly the transcriptional activity of luciferase at 10  $\mu$ M (3.8% of the induction obtained with WY 14.643). Similar inductions were detected with 0.1, 0.5, 5 and 10  $\mu$ M 4-F $_4$ t-NeuroP, with a maximum induction of 3.0%. Interestingly, PDX showed dose-response activation with significant effects starting at 0.5  $\mu$ M and a maximum of 47.7% induction for 10  $\mu$ M. Finally, lower, but still important dose-response effects were observed with NPD1, with significant induction at 1, 5 and 10  $\mu$ M, attaining a maximum of 23.2% induction. However, no induction was seen for any treatment with the tested oxylipins in cells transfected with the hPPAR $\delta$  vector.

#### 4. Discussion

A large body of evidence suggests that LC- $\omega$ 3 PUFAs might exert a part of their anti-inflammatory activities *via* their corresponding oxylipins. While enzymatic DHA-derived oxylipins, i.e. the protectins, resolvins and maresins, have been extensively investigated in the last decade (see [17] for a recent review), data regarding non-enzymatic species, i.e. the neuroprostanes, are scarce. In this comparative and dose-response study performed in human primary macrophages, we showed that the electrophilic cyclopentenone neuroprostanes were the most potent DHA-derived oxylipins tested, especially at the high doses (10  $\mu$ M). Interestingly, in our model, NPD1 had no effect at high dose (10  $\mu$ M) but became very active at the lowest dose (0.1  $\mu$ M) whereas the other oxylipins tested lost most of their effects at low doses. The other major results of this study are related to the PPARs transfection experiments showing for the first time that (1) cyclopentenone neuroprostanes activate PPAR $\gamma$ , (2) cyclopentenone neuroprostanes activate PPAR $\gamma$  stronger than the protectins and (3) NPD1 and even more PDX preferentially activate PPAR $\alpha$ .

##### 4.1. Anti-inflammatory activity of the DHA-derived oxylipins

Macrophages are able to convert DHA to a large array of oxylipins such as *n*-serie resolvins, protectins, maresin as well as hydroxy and epoxy FA and neuroprostanes which are suggested to have complex interactions to drive to inflammatory response and promote the resolution of inflammation. For instance, NPD1/PD1 biological actions have been extensively studied [39]. NPD1 regulates leukocyte infiltration, increases macrophage phagocytosis and regression from the inflammation site [40]. NPD1, resolvin D1, and 14,21-diHDHA accelerate wound healing and 14S,21RdiHDHA recovers the reparative functions of macrophages from diabetic mice [41]. In the present experiment, attention was focused on neuroprostanes and their anti-inflammatory activity which was compared to the LOX-derived protectins. All DHA-derived oxylipins investigated had an anti-inflammatory activity with 14-A $_4$ t-NeuroP, 4-F $_4$ t-NeuroP and PDX being active at 10  $\mu$ M while NPD1 had significant effects on mRNA expression of pro-inflammatory markers at 0.1  $\mu$ M. More precisely, among the four oxylipins tested, the cyclopentenone neuroprostane (i.e. 14-A $_4$ t-NeuroP) was the most potent, inducing substantial (up to 58.8%) reduction of all pro-inflammatory markers assessed. These results are consistent with the previous study conducted with this type of neuroprostane by the group of Morrow [26] who reported significant decreases of the pro-inflammatory markers iNOS and COX-2 in RAW 264.7 macrophages pre-exposed to 10  $\mu$ M 14-A $_4$ -NeuroP. In this murine macrophage cell line, the authors also reported significant effects with a lower dose of 14-A $_4$ -NeuroP (1  $\mu$ M) on the expression of iNOS but not on COX-2. Altogether, the results obtained in our model bring more

evidence that 14-A<sub>4t</sub>-NeuroP has anti-inflammatory properties and extend the findings of Musiek et al. to humans. The other neuroprostane, the 4-F<sub>4t</sub>-NeuroP, was also associated for the first time with significant anti-inflammatory properties. However, in comparison with the cyclopentenone neuroprostane, the 4-F<sub>4t</sub>-NeuroP has less pronounced effect which might be due to the absence of an electrophilic carbon limiting its interaction with signaling proteins [42]. These *in vitro* results nevertheless support preliminary results obtained in LDLR<sup>-/-</sup> mice in which we showed that F<sub>4</sub>-NeuroPs were associated with reduced atherosclerosis [25], associated with a decreased inflammation [27]. Apart from those anti-inflammatory properties, 4-F<sub>4t</sub>-NeuroP has recently been shown to exert antiarrhythmic effect in mouse cardiomyocytes at doses ranging from 10 nM to 1 μM [43]. To the best of our knowledge, this is the only other *in vitro* study reporting biological activities of the F<sub>4</sub>-neuroprostanes.

In our model, PDX induced similar decrease of pro-inflammatory mediators than the 14-A<sub>4t</sub>-NeuroP at 10 μM, but results were more variable and therefore less significant. A previous recent study performed in palmitate stimulated J774A.1 mouse macrophages reported decrease of proteins levels (in the range of about 25%) for MCP-1, TNF-α and IL-6 but also CCL-5, IL-2, iNOS and -more surprisingly- IL-10 [44]. It should be noted that these effects were observed with lower doses of PDX (10 and 100 nM). Two other *in vitro* studies using different cell models found out that PDX could reduce COX-2 activity in human platelets [45] and in LPS-induced human neutrophils [46]. Several *in vivo* experiments also support the anti-inflammatory properties of PDX which has been showed for instance to reduce the levels of TNF-α and IL-6, but also IL-1β, CXCL-1, CXCL-2 and NOS-2 by around 50% in the colon of PHIL mice that are specifically devoid of eosinophils challenged with dextran sodium sulfate and injected with 0.05 mg/kg of PDX [47]. In this study, the injection of PDX was also associated with a reduction of neutrophil infiltration in the colon and the inhibition of chemotaxis by PDX was also reported in a mice model of acute lung injury [48]. Concerning NPD1, in our model of human primary macrophages, it had no significant effect at high dose (10 μM) on any of the pro-inflammatory markers investigated but it induced significant decreases at lower doses, with up to 38.7% reduction of mRNA levels of IL-6, TNF-α and COX-2 at 0.1 μM and of CCL-3 at 1 μM. Among the four studied oxylipins, NPD1 is by far the most studied, with clear indications of its anti-inflammatory properties whereas it has never been investigated in human primary macrophages. Consistently with our findings, NPD1, at doses ranging from 0.1 to 200 nM, reduced from about 25–100% different types of pro-inflammatory markers (TNF-α, IL-6, COX-2, IL-1-β, IFNγ, CEX-1 and B94) in mouse macrophages [40,41], in rat macrophages [49], in human peripheral blood T cells [50], in primary human neuro-glial cells [22], in human glioma cells [51] or in human neuron cells [52]. *In vivo*, application of drops of NPD1 solution, 300 ng 2 times per day during 6 days or injection of 50 ng NPD1 per day during 5 days, topically reduced pro-inflammatory markers (between around 30% and 90% inhibition of IL-6, CXCL-1, CXCL-10 and CCL-20 or around 50% inhibition of TNF-α) in herpes simplex virus-infected mouse corneas [53] or diabetic mouse wound tissue [41], respectively. To our knowledge, higher (micromolar) doses had never been studied before *in vitro* and our finding with 1 and 10 μM NPD1 treatments are therefore not comparable to other studies. The anti-inflammatory properties of NPD1 were associated with reduction of neutrophil infiltration *in vivo*, in brain tissue from an ischemia-reperfusion mouse model [54], in herpes simplex virus-infected mouse corneas [53], in rabbit wounded cornea [55], in mouse induced peritonitis [39,40,50] or in kidneys from ischemia/reperfusion mouse models [49] and *in vitro*, with human neutrophils through monolayers of human microvascular endothelial cells [39].

As stated above, the four DHA-derived oxylipins tested in this study had different effects depending on the dose used. More precisely, 14-A<sub>4t</sub>-NeuroP, 4-F<sub>4t</sub>-NeuroP and PDX showed most effects on regulating pro-inflammatory genes only at the highest dose tested (10 μM)

suggesting threshold type of response with the absence of effect at low dose and an effect proportional to the dose for doses over the threshold [56]. On the contrary, NPD1 showed a different type of response with higher activity for the lowest dose tested while it becomes inactive at higher dose therefore following an inverted U shape dose response in agreement with the hormesis hypothesis. It is known that NPD1 stereoselectively and specifically binds with retinal pigment epithelial cells and neutrophils, suggesting the presence of specific receptors for NPD1 in both the immune and visual systems [57]. While the exact NPD1 receptor(s) have to be identified [58], one can indeed imagine that the absence of effect of NPD1 at high dose might be due to receptor desensitization or receptor over-saturation. Although more data would be necessary to understand completely these dose-responses, these results clearly show that different oxylipins may have the most beneficial effect at very different doses, thus pointing towards actions in different biological contexts or at different timing.

Altogether, this comparative and dose-response study strongly supports that neuroprostanes and more especially cyclopentenone neuroprostanes should be considered as major contributors of the anti-inflammatory effect of DHA. Whereas their anti-inflammatory action was mostly achieved at high dose, one might imagine that the oxidative burst associated to the first steps of the inflammatory response of macrophages could transiently generate high amount of neuroprostanes at the intracellular level. On the contrary, the fact that NPD1 was only active at low doses suggests a more subtle and enzymatically regulated activity consistent with its involvement in the resolution phase of inflammation [40].

#### 4.2. PPAR activation by the DHA-derived oxylipins

The mechanisms of action underlying the anti-inflammatory effects of LC-ω3 PUFAs are mostly associated with an inhibition of the NFκB pathway notably through PPARγ dependent mechanisms. Many studies also report that oxylipins could be potent PPAR ligands [23,24] which, together with the central role of PPARs in the regulation of inflammation and immunity in macrophage [9], strongly encouraged us to specifically investigate the ability of the DHA-derived oxylipins to bind and activate PPARs. This was done using transactivation assays in Cos-7 cells which are commonly used to study the mechanisms of action of biomolecules through PPAR activation notably in the field of oxylipins [18,21,22].

Our results showed that the four tested DHA-oxylipins were all able to bind and activate PPARα and PPARγ (but not PPARδ) with different potency depending on the sub-type of PPAR and the oxylipins. Results concerning PDX and NPD1 are in good agreement with previous studies using reporter assays in transfected cells [21,22]. It should nevertheless be noted that significant activation were observed with lower doses of PDX and NPD1 which could be due to the difference in the sensitivity of the assays, with 1 μM of rosiglitazone used in our case versus 0.1 μM rosiglitazone in the one of White et al. [21]. Concerning the neuroprostanes, to our knowledge, these results are the first to demonstrate a direct link between 4-F<sub>4t</sub>-NeuroP or 14-A<sub>4t</sub>-NeuroP and PPARγ activation. Only one other study indirectly investigated the relationship between 14-A<sub>4t</sub>-NeuroP and PPARγ using RAW macrophages and inhibitors of PPAR but failed to confirm the contribution of PPARγ in the anti-inflammatory action of 14-A<sub>4t</sub>-NeuroP [26].

Interestingly, neuroprostanes preferentially activate PPARγ while the enzymatic oxylipins PDX and NPD1 activated preferentially PPARα. This difference of ligand potency could be due the differences of structure between these oxylipins. Indeed, although the large binding pocket of PPARγ allows for high versatility of potential ligands, differences in the detailed stereochemistry of said potential ligands lead to different potential to form hydrogen bonds or covalent bonds with the binding pocket and thus differences in affinity [24].

Altogether, results of the transactivation assays suggest that the anti-inflammatory activity previously described could be mediated, at



least in part, through the binding of the DHA-derived oxylipins to PPAR $\alpha$  and PPAR $\gamma$ . Through *trans*-repression, activated PPARs have shown potential to inhibit I $\kappa$ B $\alpha$  degradation, reduce p65 nuclear translocation or its binding to DNA [59,60]. Combined with *trans*-activation mechanism this will lead to the regulation of multiple signaling pathways such as cholesterol homeostasis, but also the regulation of the immune response and inflammation.

The highest capacity of 14-A $_4$ -NeuroP to activate PPAR $\gamma$  probably contributes to explain its highest anti-inflammatory activity in monocyte-derived macrophages. This could also be due to the ability of 14-A $_4$ -NeuroP to directly inhibit NF $\kappa$ B through the inactivation of IKK as showed by Musiek et al. [26]. More precisely, the authors showed that 14-A $_4$ -NeuroP lost its capacity to inhibit LPS-induced nitrite production in RAW 264.7 macrophages after reduction of the carbonyl moiety on the cyclopentenone ring to a nonreactive alcohol. Musiek et al. also found out that a mutation of the cysteine 179 in the activation loop of IKK $\beta$  could prevent the IKK-dependent inhibition of I $\kappa$ B $\alpha$  phosphorylation triggered by 14-A $_4$ -NeuroP. 14-A $_4$ -NeuroP may thus directly inhibit IKK function (and thus NF $\kappa$ B activation) through Michael adduction of this thiol. This action of cyclopentenone rings had already been found with other molecules such as cyclopentenone prostaglandins and cyclopentenone isoprostanes [61].

Although Cos-7 transactivation assay brought significant results, it should be noted that the DHA-derived oxylipins only partly activate PPAR $\alpha$  or PPAR $\gamma$  (maximum 25% or 45% of activation respectively for PDX/PPAR $\alpha$  and 14-A $_4$ -NeuroP/PPAR $\gamma$ ) which might not be physiologically relevant in non-artificial systems. Other complementary mechanisms of action should be investigated to further understand the observed anti-inflammatory properties of DHA-derived oxylipins.

## 5. Conclusion

In conclusion, our results show that neuroprostanes and more especially cyclopentenone neuroprostanes have significant anti-inflammatory activities similar or even more pronounced than protectins supporting that neuroprostanes should be considered as important contributors to the anti-inflammatory effects of DHA. Concerning the dose-response effect, it should be noted that the tested oxylipins had different effects depending on the doses. Notably, NPD1 was active for the lowest dose while it becomes inactive at higher dose suggesting a putative interaction with receptors and desensitization or receptor oversaturation at high dose. Transactivation assays suggested that at least part of the anti-inflammatory properties of the DHA-derived oxylipins investigated might be linked to PPARs whereas complementary mechanisms of action might also contribute to the effects observed. Combined together, these results bring new insights concerning the relative contribution and dose-dependent effect of different types of DHA-derived oxylipins including the non-enzymatic neuroprostanes recently suggested to be new mediators of interest [17]. The kinetics and cross-talks between the different types of oxylipins as well as a more detailed deciphering of the mechanisms of action of DHA-derived oxylipins would be valuable leads for further understanding the roles of oxylipins in the regulation of inflammation.

## Acknowledgements

The authors would like to thank Severine Valero for her help in realizing ELISAs for this study.

Funding: This work was supported by intramural funding from INRA - Human nutrition department and the French Research on Lipids & Nutrition Group (GLN).

## References

- [1] J. Allaire, P. Couture, M. Leclerc, A. Charest, J. Marin, M.-C. Lepine, D. Talbot, A. Tcherno, B. Lamarche, A randomized, crossover, head-to-head comparison of

- eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (compared) study, *Am. J. Clin. Nutr.* 104 (2016) 280–287. <http://dx.doi.org/10.3945/ajcn.116.131896>.
- [2] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance, *Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids* 1851 (2015) 469–484. <http://dx.doi.org/10.1016/j.bbalip.2014.08.010>.
- [3] T.H. Lee, R.L. Hoover, J.D. Williams, R.I. Sperling, J. Ravalese, B.W. Spur, D.R. Robinson, E.J. Corey, R.A. Lewis, K.F. Austen, Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function, *N. Engl. J. Med.* 312 (1985) 1217–1224. <http://dx.doi.org/10.1056/NEJM198505093121903>.
- [4] D.S. Kelley, P.C. Taylor, G.J. Nelson, P.C. Schmidt, A. Ferretti, K.L. Erickson, R. Yu, R.K. Chandra, B.E. Mackey, Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men, *Lipids* 34 (1999) 317–324.
- [5] S.N. Meydani, S. Endres, M.M. Woods, B.R. Goldin, C. Soo, A. Morrill-Labrode, C.A. Dinarello, S.L. Gorbach, Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women, *J. Nutr.* 121 (1991) 547–555.
- [6] G.E. Caughey, E. Mantzioris, R.A. Gibson, L.G. Cleland, M.J. James, The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil, *Am. J. Clin. Nutr.* 63 (1996) 116–122.
- [7] K.H. Baumann, F. Hessel, I. Larass, T. Müller, P. Angerer, R. Kiefl, C. von Schacky, Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study, *Arterioscler. Thromb. Vasc. Biol.* 19 (1999) 59–66.
- [8] L.H. Sigal, Basic science for the clinician 39: NF-kappaB-function, activation, control, and consequences, *J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis.* 12 (2006) 207–211. <http://dx.doi.org/10.1097/01.rhu.0000231385.94784.e4>.
- [9] E. Rigamonti, G. Chinetti-Gbaguidi, B. Staels, Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men, *Arterioscler. Thromb. Vasc. Biol.* 28 (2008) 1050–1059. <http://dx.doi.org/10.1161/ATVBAHA.107.158998>.
- [10] M. Ricote, C.K. Glass, PPARs and molecular mechanisms of transrepression, *Biochim. Biophys. Acta* 2007 (1771) 926–935. <http://dx.doi.org/10.1016/j.bbalip.2007.02.013>.
- [11] M.W. Buczynski, D.S. Dumlao, E.A. Dennis, Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology, *J. Lipid Res.* 50 (2009) 1015–1038. <http://dx.doi.org/10.1194/jlr.R900004-JLR200>.
- [12] G.L. Milne, Q. Dai, L.J. Roberts, The isoprostanes – 25 years later, *Biochim. Biophys. Acta* 2015 (1851) 433–445. <http://dx.doi.org/10.1016/j.bbalip.2014.10.007>.
- [13] L. Balas, M. Guichardant, T. Durand, M. Lagarde, Confusion between protectin D1 (PD1) and its isomer protectin DX (PDX). An overview on the dihydroxy-docosatrienes described to date, *Biochimie* 99 (2014) 1–7. <http://dx.doi.org/10.1016/j.biochi.2013.11.006>.
- [14] M. Gabbs, S. Leng, J.G. Devassy, M. Monirujjaman, H.M. Aukema, Advances in our understanding of oxylipins derived from dietary PUFAs, *Adv. Nutr.* 6 (2015) 513–540. <http://dx.doi.org/10.3945/an.114.007732>.
- [15] J.-M. Galano, J.C.-Y. Lee, C. Gladine, B. Comte, J.-Y. Le Guennec, C. Oger, T. Durand, Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and  $\alpha$ -linolenic acids; bioactivities and potential use as biomarkers, *Biochim. Biophys. Acta* 1851 (2015) 446–455. <http://dx.doi.org/10.1016/j.bbalip.2014.11.004>.
- [16] S. Sethi, A.Y. Eastman, J.W. Eaton, Inhibition of phagocyte-endothelium interactions by oxidized fatty acids: a natural anti-inflammatory mechanism?, *J. Lab. Clin. Med.* 128 (1996) 27–38.
- [17] C.N. Serhan, N. Chiang, J. Dalli, The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution, *Semin. Immunol.* 27 (2015) 200–215. <http://dx.doi.org/10.1016/j.smim.2015.03.004>.
- [18] S. Sethi, O. Ziouzenkova, H. Ni, D.D. Wagner, J. Plutzky, T.N. Mayadas, Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha, *Blood* 100 (2002) 1340–1346. <http://dx.doi.org/10.1182/blood-2002-01-0316>.
- [19] A. Mishra, A. Chaudhary, S. Sethi, Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway, *Arterioscler. Thromb. Vasc. Biol.* 24 (2004) 1621–1627. <http://dx.doi.org/10.1161/01.ATV.0000137191.02577.86>.
- [20] J. Lefils-Lacourtablaise, M. Socorro, A. Gélouën, P. Daira, C. Debard, E. Loizon, M. Guichardant, Z. Dominguez, H. Vidal, M. Lagarde, N. Bernoud-Hubac, The eicosapentaenoic acid metabolite 15-deoxy- $\delta$ (12,14)-prostaglandin J3 increases adiponectin secretion by adipocytes partly via a PPAR $\gamma$ -dependent mechanism, *PLoS One* 8 (2013) e63997. <http://dx.doi.org/10.1371/journal.pone.0063997>.
- [21] P.J. White, P.L. Mitchell, M. Schwab, J. Trottier, J.X. Kang, O. Barbier, A. Marette, Transgenic  $\omega$ -3 PUFA enrichment alters morphology and gene expression profile in adipose tissue of obese mice: potential role for protectins, *Metabolism* 64 (2015) 666–676. <http://dx.doi.org/10.1016/j.metabol.2015.01.017>.
- [22] Y. Zhao, F. Calon, C. Julien, J.W. Winkler, N.A. Petasis, W.J. Lukiw, N.G. Bazan, Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR $\gamma$ -mediated mechanisms in Alzheimer's disease models, *PLoS One* 6 (2011) e15816. <http://dx.doi.org/10.1371/journal.pone.0015816>.
- [23] G. Krey, O. Braissant, F. L'Horsset, E. Kalkhoven, M. Perroud, M.G. Parker, W. Wahli, Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay, *Mol. Endocrinol. Baltim. Md* 11 (1997) 779–791. <http://dx.doi.org/10.1210/>

mend.11.6.0007.

- [24] T. Itoh, L. Fairall, K. Amin, Y. Inaba, A. Szanto, B.L. Balint, L. Nagy, K. Yamamoto, J.W.R. Schwabe, Structural basis for the activation of PPARgamma by oxidized fatty acids, *Nat. Struct. Mol. Biol.* 15 (2008) 924–931.
- [25] C. Gladine, J.W. Newman, T. Durand, T.L. Pedersen, J.-M. Galano, C. Demougeot, O. Berdeaux, E. Pujos-Guillot, A. Mazur, B. Comte, Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention, *PLoS One* 9 (2014) e89393. <http://dx.doi.org/10.1371/journal.pone.0089393>.
- [26] E.S. Musiek, J.D. Brooks, M. Joo, E. Brunoldi, A. Porta, G. Zanoni, G. Vidari, T.S. Blackwell, T.J. Montine, G.L. Milne, B. McLaughlin, J.D. Morrow, Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid, *J. Biol. Chem.* 283 (2008) 19927–19935. <http://dx.doi.org/10.1074/jbc.M803625200>.
- [27] C. Gladine, M. Zmojdian, L. Joumard-Cubizolles, M.-A. Verny, B. Comte, A. Mazur, The omega-3 fatty acid docosahexaenoic acid favorably modulates the inflammatory pathways and macrophage polarization within aorta of LDLR(-/-) mice, *Genes Nutr.* 9 (2014) 424. <http://dx.doi.org/10.1007/s12263-014-0424-4>.
- [28] H. Yin, E.S. Musiek, L. Gao, N.A. Porter, J.D. Morrow, Regiochemistry of neuroprostanes generated from the peroxidation of docosahexaenoic acid in vitro and in vivo, *J. Biol. Chem.* 280 (2005) 26600–26611. <http://dx.doi.org/10.1074/jbc.M503088200>.
- [29] G. Zanoni, E.M. Brunoldi, A. Porta, G. Vidari, Asymmetric synthesis of 14-A4t-neuroprostane: hunting for a suitable biomarker for neurodegenerative diseases, *J. Org. Chem.* 72 (2007) 9698–9703. <http://dx.doi.org/10.1021/jo701719f>.
- [30] C. Oger, V. Bultel-Poncé, A. Guy, L. Balas, J.-C. Rossi, T. Durand, J.-M. Galano, The handy use of Brown's P2-Ni catalyst for a skipped diene deuteration: application to the synthesis of a [D4]-labeled F4t-neuroprostane, *Chem. Weinh. Bergstr. Ger.* 16 (2010) 13976–13980. <http://dx.doi.org/10.1002/chem.201002304>.
- [31] G. Dayaker, T. Durand, L. Balas, A versatile and stereocontrolled total synthesis of dihydroxylated docosatrienes containing a conjugated E,E,Z-triene, *Chem. Weinh. Bergstr. Ger.* 20 (2014) 2879–2887. <http://dx.doi.org/10.1002/chem.201304526>.
- [32] G. Chinetti, S. Griglio, M. Antonucci, I.P. Torra, P. Delerive, Z. Majd, J.C. Fruchart, J. Chapman, S. Najib, B. Staels, Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages, *J. Biol. Chem.* 273 (1998) 25573–25580.
- [33] F.A. Fitzpatrick, W.F. Liggett, M.A. Wynalda, Albumin-eicosanoid interactions. A model system to determine their attributes and inhibition, *J. Biol. Chem.* 259 (1984) 2722–2727.
- [34] E. Raspé, L. Madsen, A.M. Lefebvre, I. Leitersdorf, L. Gelman, J. Peinado-Onsurbe, J. Dallongeville, J.C. Fruchart, R. Berge, B. Staels, Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation, *J. Lipid Res.* 40 (1999) 2099–2110.
- [35] T.J. Gray, B.G. Lake, J.A. Beamand, J.R. Foster, S.D. Gangolli, Peroxisome proliferation in primary cultures of rat hepatocytes, *Toxicol. Appl. Pharmacol.* 67 (1983) 15–25.
- [36] J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, S.A. Kliewer, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma), *J. Biol. Chem.* 270 (1995) 12953–12956.
- [37] W.R. Oliver, J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, N.L. Bodkin, M.C. Lewis, D.A. Winegar, M.L. Sznajdman, M.H. Lambert, H.E. Xu, D.D. Sternbach, S.A. Kliewer, B.C. Hansen, T.M. Willson, A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport, *Proc. Natl. Acad. Sci. USA* 98 (2001) 5306–5311. <http://dx.doi.org/10.1073/pnas.091021198>.
- [38] B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebre, I.P. Torra, P. Delerive, A. Fadel, G. Chinetti, J.C. Fruchart, J. Najib, J. Maclouf, A. Tedgui, Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators, *Nature* 393 (1998) 790–793. <http://dx.doi.org/10.1038/31701>.
- [39] C.N. Serhan, K. Gotlinger, S. Hong, Y. Lu, J. Siegelman, T. Baer, R. Yang, S.P. Colgan, N.A. Petasis, Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes, *J. Immunol.* 176 (2006) 1848–1859.
- [40] J.M. Schwab, N. Chiang, M. Arita, C.N. Serhan, Resolvin E1 and protectin D1 activate inflammation-resolution programmes, *Nature* 447 (2007) 869–874. <http://dx.doi.org/10.1038/nature05877>.
- [41] S. Hong, H. Tian, Y. Lu, J.M. Laborde, F.A. Muhale, Q. Wang, B.V. Alapure, C.N. Serhan, N.G. Bazan, Neuroprotectin/protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes, *Am. J. Physiol. Cell Physiol.* 307 (2014) C1058–C1067. <http://dx.doi.org/10.1152/ajpcell.00270.2014>.
- [42] B. Díez-Dacal, D. Pérez-Sala, Anti-inflammatory prostanoids: focus on the interactions between electrophile signaling and resolution of inflammation, *Sci. World J.* 10 (2010) 655–675. <http://dx.doi.org/10.1100/tsw.2010.69>.
- [43] J. Roy, C. Oger, J. Thireau, J. Roussel, O. Mercier-Touzet, D. Faure, E. Pinot, C. Farah, D.F. Taber, J.-P. Cristol, J.C.Y. Lee, A. Lacampagne, J.-M. Galano, T. Durand, J.-Y. Le Guennec, Nonenzymatic lipid mediators, neuroprostanes, exert the antiarrhythmic properties of docosahexaenoic acid, *Free Radic. Biol. Med.* 86 (2015) 269–278. <http://dx.doi.org/10.1016/j.freeradbiomed.2015.04.014>.
- [44] P.J. White, P. St-Pierre, A. Charbonneau, P.L. Mitchell, E. St-Amand, B. Marcotte, A. Marette, Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis, *Nat. Med.* 20 (2014) 664–669. <http://dx.doi.org/10.1038/nm.3549>.
- [45] P. Chen, E. Véricel, M. Lagarde, M. Guichardant, Poxytins, a class of oxygenated products from polyunsaturated fatty acids, potentially inhibit blood platelet aggregation, *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 25 (2011) 382–388. <http://dx.doi.org/10.1096/fj.10-161836>.
- [46] M. Liu, T. Boussetta, K. Makni-Maalej, M. Fay, F. Driss, J. El-Benna, M. Lagarde, M. Guichardant, Protectin DX, a double lipoxygenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities, *Lipids* 49 (2014) 49–57. <http://dx.doi.org/10.1007/s11745-013-3863-6>.
- [47] J.C. Masterson, E.N. McNamee, S.A. Fillon, L. Hosford, R. Harris, S.D. Fernando, P. Jedlicka, R. Iwamoto, E. Jacobsen, C. Protheroe, H.K. Eltzschig, S.P. Colgan, M. Arita, J.J. Lee, G.T. Furuta, Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis, *Gut* 64 (2015) 1236–1247. <http://dx.doi.org/10.1136/gutjnl-2014-306998>.
- [48] S. Li, Y. Zhu, J.E. Chavarro, W. Bao, D.K. Tobias, S.H. Ley, J.P. Forman, A. Liu, J. Mills, K. Bowers, M. Strøm, S. Hansen, F.B. Hu, C. Zhang, Healthful dietary patterns and the risk of hypertension among women With a history of gestational diabetes mellitus: a prospective cohort study, *Hypertension* 67 (2016) 1157–1165. <http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.06747>.
- [49] J.S. Duffield, S. Hong, V.S. Vaidya, Y. Lu, G. Fredman, C.N. Serhan, J.V. Bonventre, Resolvin D series and protectin D1 mitigate acute kidney injury, *J. Immunol.* 177 (2006) 5902–5911.
- [50] A. Ariel, P.-L. Li, W. Wang, W.-X. Tang, G. Fredman, S. Hong, K.H. Gotlinger, C.N. Serhan, The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering, *J. Biol. Chem.* 280 (2005) 43079–43086. <http://dx.doi.org/10.1074/jbc.M509796200>.
- [51] S. Hong, K. Gronert, P.R. Devchand, R.-L. Moussignac, C.N. Serhan, Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation, *J. Biol. Chem.* 278 (2003) 14677–14687. <http://dx.doi.org/10.1074/jbc.M300218200>.
- [52] W.J. Lukiw, J.-G. Cui, V.L. Marcheselli, M. Bodker, A. Botkjaer, K. Gotlinger, C.N. Serhan, N.G. Bazan, A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease, *J. Clin. Investig.* 115 (2005) 2174–2178. <http://dx.doi.org/10.1172/JCI25420>.
- [53] N.K. Rajasagi, P.B.J. Reddy, S. Mulik, P. Gjørstrup, B.T. Rouse, Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathology, *Investig. Ophthalmol. Vis. Sci.* 54 (2013) 6269–6279. <http://dx.doi.org/10.1167/iovs.13-12152>.
- [54] V.L. Marcheselli, S. Hong, W.J. Lukiw, X.H. Tian, K. Gronert, A. Musto, M. Hardy, J.M. Gimenez, N. Chiang, C.N. Serhan, N.G. Bazan, Novel docosatrienes inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression, *J. Biol. Chem.* 278 (2003) 43807–43817. <http://dx.doi.org/10.1074/jbc.M305841200>.
- [55] M.S. Cortina, J. He, T. Russ, N.G. Bazan, H.E.P. Bazan, Neuroprotectin D1 restores corneal nerve integrity and function after damage from experimental surgery, *Investig. Ophthalmol. Vis. Sci.* 54 (2013) 4109–4116. <http://dx.doi.org/10.1167/iovs.13-12075>.
- [56] V.I. Lushchak, Dissection of the hormetic curve: analysis of components and mechanisms, *Dose-Response Publ. Int. Hormesis Soc.* 12 (2014) 466–479. <http://dx.doi.org/10.2203/dose-response.13-051.Lushchak>.
- [57] V.L. Marcheselli, P.K. Mukherjee, M. Arita, S. Hong, R. Antony, K. Sheets, J.W. Winkler, N.A. Petasis, C.N. Serhan, N.G. Bazan, Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils, *Prostaglandins Leukot. Essent. Fat. Acids* 82 (2010) 27–34. <http://dx.doi.org/10.1016/j.plefa.2009.10.010>.
- [58] S. Hong, Y. Lu, Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury, *Front. Immunol.* 4 (2013) 13. <http://dx.doi.org/10.3389/fimmu.2013.00013>.
- [59] S. Kersten, B. Desvergne, W. Wahli, Roles of PPARs in health and disease, *Nature* 405 (2000) 421–424. <http://dx.doi.org/10.1038/35013000>.
- [60] B. Vergés, Clinical interest of PPARs ligands, *Diabetes Metab.* 30 (2004) 7–12.
- [61] K. Stamatakis, D. Pérez-Sala, Prostanoids with cyclopentenone structure as tools for the characterization of electrophilic lipid-protein interactions, *Ann. N.Y. Acad. Sci.* 1091 (2006) 548–570. <http://dx.doi.org/10.1196/annals.1378.096>.